Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC1187
TNBC
Basal A
LY294002
PI3K
PI3K
7812.029
uM
inf
inf
1.0500 1.0500 0.0000 -0.0475
-56.7271
0.9642
CAMA-1
HR+
Luminal
Ribavirin
15348.211
uM
inf
inf
1.0500 1.0500 0.0000 -0.0410
-5.7835
0.7490
HCC1187
TNBC
Basal A
FTase Inhibitor I
Ftase
MAPK
10753.154
uM
inf
inf
1.0162 1.0162 0.0000 -0.0376
-5.9291
1.4444
LY2
HR+
Luminal
PS-1145
IKK
NFKB
10380.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0461
-60.9713
1.4916
Hs 578T
TNBC
Basal B
AG1024
IGF1R
RTK
7473.066
uM
inf
inf
1.0500 1.0500 0.0000 -0.0434
-6.5378
2.3582
MDA-MB-361
HER2amp
Luminal
Sulindac sulfide
COX1/2
COX
10643.136
uM
inf
inf
1.0500 1.0500 0.0000 -0.0432
-6.6439
0.5141
MDA-MB-231
TNBC
Basal B
Sirolimus
MTOR
MTOR
7504.069
uM
inf
inf
1.0328 1.0328 0.0000 -0.0478
-66.7663
1.8361
HCC1428
HR+
Luminal
PS-1145
IKK
NFKB
7442.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0407
-6.6988
0.7805
Hs 578T
TNBC
Basal B
Methotrexate
DHFR
Metabolism
7475.084
uM
inf
inf
1.0500 1.0500 0.0000 -0.0415
-7.3003
2.7804
SUM159PT
TNBC
Basal B
PS-1145
IKK
NFKB
7531.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0370
-7.5867
3.4461
HBL-100
Unknown
Unknown
Cetuximab
EGFR
ErbB
7807.042
uM
inf
inf
1.0098 1.0098 0.0000 -0.0392
-7.7987
2.0250
MDA-MB-415
HR+
Luminal
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7510.094
uM
inf
inf
1.0500 1.0500 0.0000 -0.0419
-8.1247
0.8152
UACC-812
HER2amp
Luminal
Cetuximab
EGFR
ErbB
10267.026
uM
inf
inf
1.0500 1.0500 0.0000 -0.0438
-8.1346
0.3125
MCF 10A
NM
Basal B
PS-1145
IKK
NFKB
7484.065
uM
inf
inf
1.0207 1.0207 0.0000 -0.0389
-8.5103
2.3857
MX1
Unknown
Unknown
PS-1145
IKK
NFKB
7523.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0407
-9.0127
0.7668
Hs 578T
TNBC
Basal B
Purvalanol A
CDK1
CDK
7475.067
uM
inf
inf
1.0500 1.0500 0.0000 -0.0408
-9.2547
2.4078
HCC1569
HER2amp
Basal A
PD 98059
MEK
MAPK
12523.152
uM
inf
inf
1.0310 1.0310 0.0000 -0.0401
-9.8795
0.8423
SUM225CWN
HER2amp
Basal A
Celecoxib
COX2
COX
10579.136
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.6876
BT-483
HR+
Luminal
Cetuximab
EGFR
ErbB
9186.026
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.5108
MDA-MB-436
TNBC
Basal B
LY294002
PI3K
PI3K
7898.029
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.7130
Hs 578T
TNBC
Basal B
Erlotinib
EGFR
ErbB
7475.091
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
2.6839
SUM1315MO2
TNBC
Basal B
GSK1838705A
IGF1R
RTK
7528.071
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.5828
BT-20
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
5904.095
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.6537
MDA-MB-361
HER2amp
Luminal
SB-3CT
MMP2/9
MMP
12379.168
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.4672
LY2
HR+
Luminal
L-779450
BRAF
MAPK
10816.149
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.4545